Kornimate/medical-research-clean huggingface dataset:
exhaled breath condensate biomarkers and cough in ipf

Conditions: Idiopathic Pulmonary Fibrosis

Summary: analysis of exhaled breath condensate biomarkers and cough severity in patients with idiopathic pulmonary fibrosis.

this study will aim to investigate the levels of the reactive oxygen species (ros) 8-isoprostane in idiopathic pulmonary fibrosis patients' exhaled breath condensate (ebc). ebc samples will be collected using rtube, prior to analysis for levels of 8-isoprostane. an acceptability assessment will be performed for this non-invasive method of ebc collection through a non-validated questionnaire. a regression analysis will then be performed for 8-isoprostane levels against the severity of the patient's cough, assessed through the use of the visual analogue scale for cough (vas), the king's brief interstitial lung disease questionnaire (kbild), the medical research council (mrc) dyspnoea scale and the leicester cough questionnaire. alongside this an exploratory comparison of cough scores and 8 isoprostane concentration between patients with and without honeycombing and traction bronchiectasis.

Eligibility criteria:
inclusion criteria: * male or female above the age of 40 * ipf diagnosed by a multi-disciplinary team meeting following review of clinical history, thoracic high resolution computed tomography (hrct) and/or surgical lung according to international guidelines exclusion criteria: * a recognised significant co-existing respiratory disease, defined as a respiratory condition that exhibits a clinically relevant effect on respiratory symptoms and disease progression as determined by the principal investigator following multi-disciplinary discussion. for example, patients with bronchiectasis will only be included if the bronchiectasis is deemed to be traction bronchiectasis as a result of idiopathic pulmonary fibrosis * airflow obstruction defined as a forced expiratory volume at one second over forced vital capacity (fev1/fvc) \<60% predicted or a residual volume greater than 120% predicted * significant medical ,surgical or psychiatric disease that in the opinion of the patient's attending physician would exhibit a clinically relevant effect on the patient's health related quality of life * the patient is unable to provide written informed consent
pediatric metabolic syndrome study

Conditions: Metabolic Syndrome; Overweight and Obesity; Cardiovascular Risk Factor

Summary: the pediatric metabolic syndrome study is an observational study being conducted at the medical university of south carolina to investigate cardiometabolic risk parameters in obese subjects ages 4 to 21. a detailed assessment is performed on eligible subjects including fasting labwork, anthropometrics, nutrition analysis, body composition testing, echocardiography, and carotid imt measurements.


Eligibility criteria:
inclusion criteria: age 4 to 21 years history of obesity (bmi at or over the 95th% for age/gender) exclusion criteria: age below 4 or above 21 years no history of obesity current pregnancy current chronic oral steroid use current insulin use

Keywords: pediatric metabolic syndrome
a research study looking at how oral semaglutide works in people with type 2 diabetes in the netherlands, as part of local clinical practice

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of the study is to collect information on how rybelsus® works in people with type 2 diabetes and to see if rybelsus® can lower their blood sugar levels. participants will get rybelsus® as prescribed to them by the study doctor. the study will last for about 8-10 months. participants will be asked to complete a questionnaire about how they take their rybelsus® tablets. participants will complete this questionnaire during their normally scheduled visit with the study doctor. participants will be asked to complete some questionnaires about their diabetes treatment. participants will complete these during their normally scheduled visits with the study doctor.


Eligibility criteria:
inclusion criteria: * signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) * diagnosed with type 2 diabetes mellitus * the decision to initiate treatment with commercially available oral semaglutide has been made by the patient/legally acceptable representative (lar) and the treating physician based on local label before and independently from the decision to include the patient in this study * male or female, age above or equal to 18 years at the time of signing informed consent * available hba1c value less than or equal to 90 days prior to the 'informed consent and treatment initiation visit' (v1) or hba1c measurement taken in relation with the 'informed consent and treatment initiation visit'(v1) if in line with local clinical practice * treatment naïve to injectable glucose-lowering drug(s). an exception is short-term insulin treatment for acute illness for a total of less than or equal to 14 days exclusion criteria: * previous participation in this study. participation is defined as having given informed consent in this study * treatment with any investigational drug within 30 days prior to enrolment into the study * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
the application of fluorescence laparoscopy in the treatment of adenocarcinoma of the esophagogastric junction

Conditions: Fluorescence Laparoscopy; Adenocarcinoma of the Esophagogastric Junction

Summary: the fluorescent laparoscopic technique would be applied to the radical resection of gastric cancer at the junction of esophagus and stomach, and compared with the traditional laparoscopic radical resection of gastric cancer to find a better surgical method for patients


Eligibility criteria:
inclusion criteria: - 1. all cases should be diagnosed as adenocarcinoma of the esophagogastric junctionncer by histology. the tumor is within 1 cm above or 2 cm below the anatomic cardia. the clinical stage is t1-3, nx, m0 for gastric cancer which can undergo the laparoscopic surgery. 2. eastern cooperative oncology group (ecog) scale 0-2 3. heart, lung, liver, and kidney function can tolerate operation 4. patients and their families are able to understand and be willing to participate in this clinical study and to sign informed consent. exclusion criteria: 1. history of stomach malignant disease 2. recent diagnosis of other malignant tumors (except for papillary carcinoma of the thyroid gland and basal cell carcinoma of the skin) 3. patients with obstruction, perforation, bleeding requiring emergency surgery 4. a history of abdominal surgery (which makes it difficult to perform laparoscopic procedures), severe systemic disease such as diabetes, severe chronic lung disease, cirrhosis, other malignant diseases 5. combined stomach multiple carcinomas 6. with a history of serious mental illness 7. pregnant or lactating women 8. the researchers believe that the patients are unsuitable to participate in the researchers with other cases. -

Keywords: fluorescence laparoscopy adenocarcinoma of the esophagogastric junction (aeg)
the impact of doulas in early pregnancy management

Conditions: Uterine Evacuation

Summary: the purpose of the study is to examine the impact of doula support for women undergoing a manual vacuum aspiration (mva) for an early pregnancy failure or undesired pregnancy.

as a means of providing emotional support and physical comfort for all pregnant women, doulas have emerged in recent years in the world of clinical abortion care. traditionally, doulas are non-medical individuals trained to provide emotional support, pain management strategies, relaxation techniques, and information to pregnant women during labor. the positive impact of doulas on obstetrical health outcomes and patient satisfaction is well accepted. women with the support of a doula have been shown to have shorter labor, and rate birth as less difficult and more satisfying, than do mothers without doula support. they also report a greater ability to cope with labor and require less epidural and iv pain medication. in recent years, the term full spectrum doula has emerged to describe doulas who extend their supportive services to women at any stage of a pregnancy, including the management of a miscarriage or undesired pregnancy ending in abortion. the doula project, created in 2007 in new york city, and the bay area doula project, founded in 2011in san francisco, were two of the first organized efforts to train doulas to provide abortion care and are now the largest in the united states. scientific research on the impact of doulas during abortion and miscarriage management has been limited, but anecdotal reports from patients and providers suggest a positive impact on patient satisfaction. in this study we aim to test the impact of doulas on the physical, emotional, and overall experience among women undergoing a mva for an early pregnancy failure or undesired pregnancy at the penn family planning and pregnancy loss center. we also aim to assess the impact of doula support from the medical assistants perception.

Eligibility criteria:
inclusion criteria: * female 18 years or older who is choosing to have a surgical procedure for the management of early pregnancy failure or undesired pregnancy. * pregnancy is not because of an incident of sexual assault or rape. exclusion criteria: * pregnancy is due to an incident of sexual assault or rape.

Keywords: doula pain management miscarriage abortion
optimizing care for children hospitalized with community-acquired pneumonia: short-course therapy

Conditions: Community-acquired Pneumonia

Summary: children are commonly hospitalized because of community-acquired pneumonia (cap). there are multiple high-quality randomized trials of short-course antibiotic therapy (3-5 days of treatment) for adults hospitalized with cap - but there is very little evidence in children. we intend to do a pilot rct of short-course (3-5 days) vs standard-duration (8-10 days) antibiotic therapy for children hospitalized for cap.


Eligibility criteria:
inclusion criteria: * - children with a history of fever who are hospitalized with cap (ie. 'severe cap') as per the clinical team and who have abnormal chest imaging (eg. radiograph, ultrasound) will be eligible. they must also have at least one of the following: 1. documented tachypnoea (\>60 bpm for age \ 50 bpm for 1-2 y, \>40 bpm for 2-4 y, and \>30 bpm for \>4 y); 2. cough on exam or by history; 3. increased work of breathing on exam; or 4. auscultatory findings (eg. focal crackles, bronchial breathing) consistent with cap. exclusion criteria: * children will be excluded if: antibiotics have been discontinued; they received \>3 days of effective antibiotic treatment (excluding macrolide treatment) prior to hospitalization; there is supplemental oxygen use or fever within the past 24 h; more than 5 days elapsed since admission; the attending clinical team does not wish to use oral amoxicillin for treatment (because of allergy or any other reason); or the child is taking coumadin-based anticoagulants or tetracycline-type antibiotics (because of potential interactions with amoxicillin). children will also be excluded if they have any of the following: chronic lung disease, congenital heart disease (requiring treatment or with exercise restrictions), malignancy, immunodeficiency (primary, acquired, or iatrogenic), a separate episode of pneumonia previously diagnosed within the past 2 weeks, or lung abscess diagnosed within the past six months. children will not be eligible to participate more than once.
statin and epidural steroid injection

Conditions: Low Back Pain After Epidural Steroid Injection; Quality of Life After Epidural Steroid Injection

Summary: the impact of statin use on response to epidural steroid injections remains unknown and may well increase the effect considering the substantial anti-inflammatory properties. we thus tested the primary hypothesis that patients taking statins before and after the procedure will have lower vas scores compared to patients not on statins. secondarily we tested the hypothesis that statin users will have improved quality of life evaluated with short form 36 (sf 36).

low back pain is one of the most common complaints for physician office visits and is the most common disorder requiring interventional pain treatment in usa. fluoroscopy-assisted transforaminal anterior epidural steroid injections (taesi) are more commonly preferred for treatment of low back pain. most of the time epidural steroid injections are supplemented with different analgesic combinations due to insufficient analgesia. recent reports have revealed immunomodulatory and anti-inflammatory activities for statins in vivo and in vitro. statins have very recently been shown to alleviate neuropathic pain in the rat model. however, the impact of statin use on response to epidural steroid injections remains unknown and may well increase the effect considering the substantial anti-inflammatory properties. we thus tested the primary hypothesis that patients taking statins before and after the procedure will have lower vas scores compared to patients not on statins. secondarily we tested the hypothesis that statin users will have improved quality of life evaluated with short form 36 (sf 36).

Eligibility criteria:
inclusion criteria: * indication for taesi given by blinded pain physician exclusion criteria: * known allergy to steroids * indication for surgery * unstable opioid use * drug or alcohol abuse within 6 months

Keywords: low back pain epidural steroid injection statin quality of life
evaluation of body composition improvement with visceral adiposity-focused anti-obesity telehealth program

Conditions: Obesity; Cardiovascular Diseases; Metabolic Syndrome; Metabolic Disease

Summary: a retrospective review of body composition changes in patients who participate in a 9-week non-invasive intensive health care provider supervised weight loss program as an overall cohort and in sub-cohorts of interest.


Eligibility criteria:
inclusion criteria: * men and women 18 years of age and older, who enroll in the weight loss program are eligible for inclusion of the data review. exclusion criteria: * pregnancy or breastfeeding * current treatment of cancer * major organ transplant with immunosuppressant medication, * adult with a strict vegetarian diet, * certain psychiatric conditions (schizophrenia, bipolar disorder, manic depression) * adults with a bmi \< 25.0 and no cardiovascular or metabolic comorbidities

Keywords: visceral adiposity bmi body composition obesity cardiovascular disease metabolic syndrome metabolic disease
vitamin b complex and diabetic nephropathy in type 1 diabetes

Conditions: Plasma Homocysteine; HbA1c Level

Summary: homocysteine levels have been found elevated in t1dm patients with diabetic nephropathy (dn) due to several causes, including dietary deficiencies. hyperhomocysteinemia induces renal injury and is associated with increasing urinary albumin excretion(uae). therefore, the investigators performed a randomized-controlled trial of oral supplementation with vitamin b complex as an adjuvant therapy for nephropathy in pediatric patients with t1dm and assessed its relation to homocysteine levels, glycemic control, microalbuminuria and cystatin c as a marker of nephropathy.

this trial included 80 vitamin b12-deficient t1dm patients with nephropathy, despite oral angiotensin-converting enzyme inhibitors . enrolled patients aged 12-18 years with at least 5 years disease duration and hba1c ≤8.5%. patients were randomly assigned into two groups; intervention group who received vitamin b complex once daily orally . the other group did not receive any supplementation and served as a control group. both groups were followed-up for 12 weeks with assessment of plasma homocysteine, hba1c, cystatin c and uae.

Eligibility criteria:
inclusion criteria: * patients with type 1 diabetes. * patients aged 12-18 years with at least 5 years disease duration. * active diabetic nephropathy in the form of microalbuminuria (urinary albumin excretion \[uae\] 30-299 mg/g creatinine in two of three samples over a 3- to 6- months period despite angiotensin converting enzyme inhibitors) * hemoglobin a1c (hba1c) ≤8.5% * patients on regular visit to clinic. * patients on regular insulin therapy. exclusion criteria: patients were excluded if they have any of the following: * patients with history of liver disease or any disorder likely to impair liver functions or elevated liver enzymes. * patients with any evidence of renal impairment due to cause other than diabetes. * patients with hypertension. * hepatitis virus infection (b or c) or any evidence of infection. * taking any vitamins or food supplements one month before study. * participation in a previous investigational drug study within 3 months preceding screening.
inspiratory muscle training in patients with autonomic neuropathic

Conditions: Diabetes Mellitus; Diabetic Autonomic Neuropathy

Summary: this study describes a controlled randomized clinical trial to evaluate the effect of inspiratory muscle training in patients with diabetic autonomic neuropathy.

the diabetic autonomic neuropathy (nad) is a common complication of diabetes mellitus (dm), both of the type 1 diabetes mellitus (dm1) as of the type 2 diabetes mellitus (dm2). the results of this study, would help to reveal the degree of commitment generated by nad in respiratory muscle strength, can also enable the development of a new therapeutic approach, such non-pharmacological (respiratory muscle training), with a view to improve the respiratory muscle strength and alleviate the autonomic dysfunction in these patients.

Eligibility criteria:
inclusion criteria: * diabetic autonomic neuropathy * age between 36 and * 70 years old and signed in informed consent form exclusion criteria: * presence of congestive heart failure * chronic obstructive pulmonary disease (fev1 \< 70% and/or fev1%\< 80 * class ii or iii obesity (body mass index \> 35)

Keywords: diabetes mellitus autonomic neuropathy inspiratory muscle training
prevalence and long-term impact of non-atherosclerotic cad

Conditions: Myocardial Infarction

Summary: despite a relatively high prevalence of non-atherosclerotic coronary artery disease (nacad) among young women, the majority of these abnormalities were misdiagnosed in this population, and thus treatments were not targeted adequately in this patient population. furthermore, the short and long-term cardiovascular outcomes of young women with nacad have not been evaluated. given the importance of nacad in young women, the challenges of diagnosis and subsequent treatment, and unknown outcomes with nacad, we propose a prospective registry to further evaluate this population. we propose to evaluate young women (age \< or equal to 55) presenting with myocardial infarction (mi) prospectively, to diagnose the etiology of mi differentiating atherosclerotic versus nacad, to correlate the prevalence of fmd in other vascular territory, and to evaluate the long-term outcome of young women with nacad in comparison to those with atherosclerotic cad over a 5-year follow-up.

all women aged 55 or younger having a coronary angiogram for acute coronary syndrome (acs) will be approached prior to their procedure. a pregnancy test will be performed (standard for pre-menopausal women due to potential radiation exposure). if the cause of the heart attack is uncertain (eg no obvious infarct-related narrowing or occlusion), intravascular ultrasound or optimal coherence tomography will be performed within the context of the angiogram to better view the artery wall. a picture of the iliac and renal arteries will be accomplished by aortography (one dye shot down the aorta); in the case that the renal arteries are not well visualized, selective renal angiography will be performed (catheter at the entry to the renal artery). in the case of suspected non-atherosclerotic abnormalities, a head ct angiogram wil be performed. referral to appropriate specialists for detected abnormality will occur. if symptoms continue, the subject will be followed by a cardiologist. a research coordinator will contact the subject at 1, 6 and 12 months and then annually to collect data on medications, hospitalization and symptoms.

Eligibility criteria:
inclusion criteria: * women aged 55 or younger with a troponin positive acute coronary syndrome (st and non-st elevation myocardial infarction or acute coronary syndrome (acs)) having a coronary angiogram * negative pregnancy test for women of child bearing age exclusion criteria: * creatinine clearance \<50 * not willing to undergo an angiogram * troponin negative acs

Keywords: myocardial infarction dissection coronary fibromuscular dysplasia coronary ectasia atherosclerotic coronary artery disease coronary vasculitis coronary embolism congenital coronary anomaly
pollutant altered allergic responses

Conditions: Allergic Rhinitis; Allergy

Summary: this study is designed to investigate whether exposure to particulate air pollution increases the allergic response to allergens. research studies suggest that symptoms in individuals with allergies may be aggravated by exposure to particulate air pollution. we sought to experimental determine this by exposing human volunteers to combustion particles, a component of air pollution, and then challenge them with an allergen such as ragweed or oak tree pollen. using biological tests we can measure whether the allergen response is magnified by prior particulate exposure.

to study whether particulates enhance the allergic response, we chose the upper airway as a model of allergic inflammation and nasal lavage as a non-invasive method for obtaining samples. the nasal cavity is both an excellent model of allergic inflammation and provides an easily accessible site for study. we measured inflammatory cells and cytokines in the nasal lavage fluid. our specific hypothesis was that particulate exposure prior to allergen challenge would enhance inflammatory cell recruitment and expression of inflammatory cytokines.

Eligibility criteria:
adult without a history of asthma or respiratory disease.

Keywords: allergy air pollution lung function inflammation
extension study of two doses of linsitinib in subjects with active, moderate to severe thyroid eye disease (ted)

Conditions: Thyroid Eye Disease; Graves Orbitopathy; Endocrine System Diseases; Eye Diseases; Thyroid Associated Ophthalmopathy; Graves Ophthalmopathy; Thyroid Diseases; Orbital Diseases; Proptosis; IGF1R; Exophthalmos; Hashimoto

Summary: the overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior vgn-ted-301 through week 24. these subjects include vgn-ted-301 week 24 proptosis non-responders or subjects who relapse during the follow-up period of vgn-ted-301.


Eligibility criteria:
inclusion criteria: * subject who completed the 24-week double-mask period of vgn-ted-301 and are proptosis non-responders (\< 2 mm reduction in proptosis in the study eye) at week 24 of vgn-ted-301 study or proptosis responders at week 24 who relapse during the follow-up period of vgn-ted-301 * subject has not received any treatment for ted since week 24 of vgn-ted-301 * subjects must be euthyroid with the participant's baseline disease under control or have mild hypo- or hyperthyroidism (defined as free thyroxine \[ft4\] and free triiodothyronine levels \[ft3\] \<50% above or below the normal limits) at baseline. every effort should be made to correct mild hypo- or hyperthyroidism promptly and maintain the euthyroid state for the duration of the clinical trial * does not require immediate ophthalmic surgery, radiotherapy to orbits or other ophthalmological intervention at the time of baseline and is not planning for any such treatment during the course of the study exclusion criteria: * the exclusion criteria of protocol vgn-ted-301 also apply to this extension study.